文献速递肾癌与肾肿瘤

术前增强CT主动脉-病灶衰减差值鉴别肾肿瘤良恶性

Using Aorta-Lesion-Attenuation Difference on Preoperative Contrast-enhanced Computed Tomography Scan to Differentiate Between Malignant and Benign Renal Tumors.
PubMed 文献 · Urology · 2018-12-12

本研究回顾性分析227例因小实体肾 masses 行肾部分切除术患者的术前增强CT与病理,计算主动脉-病灶衰减差值(ALAD)。肾实质期ALAD以24 HU为阈值鉴别恶性病变与嗜酸细胞瘤的敏感度84%、特异度86%、AUC 0.86;鉴别嫌色细胞癌与嗜酸细胞瘤的AUC达0.98。ALAD有助于处理穿刺活检诊断不明的嗜酸细胞性肿瘤。

要点

  • 肾实质期ALAD以24 HU阈值鉴别恶性与嗜酸细胞瘤,AUC 0.86。
  • ALAD鉴别嫌色细胞癌与嗜酸细胞瘤AUC 0.98,敏感度100%。
  • ALAD或有助于穿刺活检诊断不明嗜酸细胞性肿瘤的管理。

核心结论

  • ALAD能较好鉴别嫌色细胞肾细胞癌与嗜酸细胞瘤,可能辅助穿刺活检诊断不明嗜酸细胞性肿瘤的管理。
  • ALAD在常规临床应用前仍需进一步验证。

研究设计与样本

  • 回顾性综述,纳入因小实体肾 masses 行肾部分切除术患者的术前CT扫描与手术病理,共227例。
  • ALAD通过同一图像层面主动脉与病灶的Hounsfield单位(HU)差值计算。

主要发现

  • 肾实质期ALAD以24 HU为阈值鉴别恶性病理与嗜酸细胞瘤:敏感度84%、特异度86%、阳性预测值98%、阴性预测值33%,AUC 0.86(95%CI 0.77-0.96)。
  • 肾实质期ALAD以24 HU为阈值鉴别嫌色细胞肾细胞癌与嗜酸细胞瘤:敏感度100%、特异度86%、阳性预测值75%、阴性预测值100%,AUC 0.98(95%CI 0.91-1.00)。

关键数值与推荐

  • 肾实质期ALAD阈值24 HU用于鉴别恶性病理与嗜酸细胞瘤。
  • 肾实质期ALAD阈值24 HU用于鉴别嫌色细胞肾细胞癌与嗜酸细胞瘤。

临床怎么用

  • 对于穿刺活检诊断为嗜酸细胞性肿瘤但性质不明的患者,可参考肾实质期ALAD以24 HU为阈值辅助鉴别嫌色细胞癌与嗜酸细胞瘤。

局限性

  • 回顾性研究设计。
  • ALAD在常规临床应用前需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the ability of Aorta-Lesion-Attenuation Difference (ALAD) to differentiate malignant renal tumors from renal oncocytomas. METHODS: A retrospective review of preoperative computed tomography (CT) scans and surgical pathology was performed on patients undergoing partial nephrectomy for small, solid renal masses. ALAD was calculated by measuring the difference in Hounsfield units (HU) between the aorta and the lesion of interest on the same image slice on preoperative CT scan. The discriminative ability of ALAD to differentiate malignant pathology from oncocytoma was evaluated by sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and area under curve (AUC) using receiver operating characteristic analysis. RESULTS: A total of 227 preoperative CT scans and corresponding pathology reports were reviewed. ALAD values were calculated during the excretory and nephrographic phases. Nephrographic ALAD was able to differentiate malignant pathology from oncocytoma using a HU threshold of 24 with a sensitivity of 84%, specificity of 86%, PPV of 98%, and NPV of 33%. The AUC for malignant pathology vs oncocytoma was 0.86 (95% confidence intervals 0.77-0.96). Nephrographic ALAD was able to differentiate chromophobe renal cell carcinoma (RCC) from oncocytoma using a HU threshold of 24 with a sensitivity of 100%, specificity of 86%, PPV of 75%, and NPV of 100%. The AUC for chromophobe RCC vs oncocytoma was 0.98 (95% confidence intervals 0.91-1.00). CONCLUSION: ALAD discriminates well between chromophobe RCC and oncocytoma, which may aid in the management of patients with indeterminate diagnoses of oncocytic neoplasm on diagnostic needle biopsy. Further validation of ALAD will be necessary prior to routine use in clinical practice.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Grajo JR, Terry RS, Ruoss J, et al. Using Aorta-Lesion-Attenuation Difference on Preoperative Contrast-enhanced Computed Tomography Scan to Differentiate Between Malignant and Benign Renal Tumors. Urology. 2018. PMID: 30552939. doi:10.1016/j.urology.2018.11.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。